IASP 2024: Discrepancies among opioid use guidelines for chronic pain could compound addiction
The session at IASP 2024 highlighted the likely risk of opioid therapy in chronic pain management resulting in a risk of opioid use disorder (OUD).
Neurology
UCB to divest China neurology and allergy business for $680m
Organon and Lilly expand deal for migraine treatment to new markets
UAE approves BioArctic and Eisai’s Leqembi for Alzheimer’s disease
FDA approves Servier’s VORANIGO for IDH-mutant Grade 2 glioma
Genentech and Sangamo to develop neurodegenerative disease therapies
NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
